

# Quantitative forensic toxicology

Consideration, experimentation  
and implementation



Discover the latest science  
with product experts  
and industry insiders





**cfsre**

Redefining Excellence  
in Forensic Science



**NPS**

**DISCOVERY**


# Utility of Standard Addition for Quantitative Forensic Toxicology: Consideration, Experimentation, and Implementation

**Alex J Krotulski, PhD – Associate Director (CFSRE) & Program Manager (NPS Discovery)**

Trendsetters – SCIEX – April 27, 2021


# Standard Addition

- **Definition:** A type of quantitative analysis approach whereby the standard is added directly to the aliquots of analyzed sample
  - Internal calibration model (as opposed to an external calibration model)
- Various scientific areas use standard addition
- Mechanism to provide accurate and reliable quantitative results in the absence of a traditionally validated assay
  - Rarely encountered substances
  - Novel Psychoactive Substances (NPS)




# Standard Addition

- Briefly... how standard addition works:




# Standard Addition

- Briefly... how standard addition works:





# Standard Addition

- Briefly... how standard addition works:




# Standard Addition

- Briefly... how standard addition works:



# Standard Addition

- Briefly... how standard addition works:





# Selecting “Up-Spike” Concentrations

- Can be difficult to impossible (at times)
  - Use screening data for estimation
- **General approaches:**
  - If you know estimated concentration:
    - I.e., approximately 10 ng/mL
    - Up-spike at 50%, 100%, and 200%
    - More specific, but less comprehensive and more time consuming
  - If you know ball-park concentration:
    - I.e., somewhere around 1-10 ng/mL
    - Up-spike at 0.2, 2, and 20 ng/mL for all
    - Span two orders of magnitude or more, can be comprehensive, can drop data point\*
- **Good:**
  - Estimated concentration: 7 ng/mL
  - Up-spike at 4, 10, and 20 ng/mL
  - Actual concentration: 5.8 ng/mL
- **Bad:**
  - Estimated concentration: 500 ng/mL
  - Up-spike at 2, 5, and 10 ng/mL
  - Actual concentration: ??? ng/mL
  - *OR*
  - Estimated concentration: ??? ng/mL
  - Up-spike at 5, 10, and 50 ng/mL
  - Actual concentration: 0.2 ng/mL
- **Up-spikes *should* bracket your final conc.**

# CONSIDERATIONS



# Considerations

- **The Good and The Bad:**

- **Pros:**


- “Self-validating” approach
- Different requirements for *validation*
- Resource savings on small scale
- When executed properly, more accurate

- **Cons:**

- Consumed sample volume (2+ mL per assay)
- Need to know a ballpark quantitative value
- For 10+ samples, can become time consuming and resource consuming

- **Additional Considerations:**

- Desired quantitative range
- Instrumentation
  - GC-MS vs. LC-MS/MS vs. LC-HRMS
- Matrix type
  - Tissue, vitreous, bile, etc.
- Matrix effects
  - Can you replicate postmortem blood?
- Internal standard
- Etc.



# Considerations

- Standard addition **can not** be applied without assessment of the analytical technique

I-SECTION: PERSPECTIVE

www.rsc.org/analyst | The Analyst

## Standard additions: myth and reality†


Stephen L. R. Ellison<sup>a</sup> and Michael Thompson<sup>b</sup>

DOI: 10.1039/b717660k

Standard additions is a calibration technique devised to eliminate rotational matrix effects in analytical measurement. Although the technique is presented in almost every textbook of analytical chemistry, its behaviour in practice is not well documented and is prone to attract misleading accounts. The most important limitation is that the method cannot deal with translational matrix effects, which need to be handled separately. In addition, because the method involves extrapolation from known data, the method is often regarded as less precise than external calibration (interpolation) techniques. Here, using a generalised model of an analytical system, we look at the behaviour of the method of standard additions under a range of conditions, and find that, if executed optimally, there is no noteworthy loss of precision.

### Recommendations for standard additions

1. Make sure that the analytical method is effectively linear over the whole of the required working range.
2. Make sure that any translational interference is eliminated separately.
3. Only one level of added analyte is necessary, with repeated measurements if better precision is required.
4. Let the concentration of the added analyte be as high as is consistent with linearity, and ideally at least five times the original concentration of analyte.



**Figure 1.** Different types of matrix effect on the analytical signal. Matrix A is the calibration matrix. With Matrix B a rotational effect changes the size of the signal derived from the analyte, but not the intercept. With Matrix C the intercept has been shifted by a translational effect, but the slope is unaffected. At point X the two matrix effects fortuitously have the same outcome.

# EXPERIMENTATION



# Experimentation

- **Method development and workflow** (*same a traditionally validated assay*)
  - Analytical method
  - Spiking mixes / internal standard
  - Sample preparation protocol / extraction
- **Example:**
  - SCIEX TripleTOF® 5600+ LC-MS/MS System
  - Column, mobile phase, and gradient
  - MRM transitions / MS parameters
  - Isotonitazene and fentanyl-D5 / 0.1 and 1 ng/μL
  - Liquid-liquid extraction



**Table I.** LC Gradient Conditions

Time (min)	%A	%B	Flow (mL/min)
Initial	50	50	0.4
1.0	50	50	0.4
4.0	5	95	0.4
5.0	5	95	0.4
5.1	50	50	0.4
6.0	50	50	0.4

**Table II.** MRM Parameters

Analyte	Cone (V)	Precursor (m/z)	Collision (V)	Product (m/z)	Dwell (s)
Isotonitazene	50	411.2	46	106.9	0.053
			22	100.0	0.053
			44	72.0	0.053
Fentanyl-d <sub>5</sub>	56	342.2	24	188.0	0.053
			40	105.0	0.053

# Experimentation

- **Method verification** (or “validation”)

- Modeled after ASB Standard 036: *Standard Practices for Method Validation in Forensic Toxicology*
- These are our proposed experiments to assess the use of standard addition

## Required:

- Linearity (target range)
- Limit of detection
- Carryover
- Interferences

## May be required:

- “Controls” (accuracy and precision)
- Stability studies
- Recovery

## Not required:

- Ion suppression / enhancement
- Dilution integrity



cfsre



NPS DISCOVERY

# IMPLEMENTATION





# Implementation



[Screening] – Analysis of sample(s) by LC-QTOF-MS





Method development and verification



[Confirmation] – Application to authentic sample(s)



Calculation of concentration (x-intercept)





New Session


#	✓	Mass	RT	Isotope	Library	Formula	Name	Formula	Mass (Da)	Adduct	Extraction Mass (Da)	Expected RT (min)	Fragment Mass (Da)	Found At Mass (Da)	Error (ppm)	Isotope Ratio Difference (%)	Found At RT (min)	RT Delta (min)	Intensity	Area
2382	✓	✓	✓	✓	✓	✓	Fentanyl	C22H28N2O	336.22016	H+	337.22744	6.2	216.1384	337.22772	0.8	6.2	6.35	0.15	2366	108
2509	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7		343.07794	0.2	8.1	7.86	0.16	135492	8755
2510	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7	314.0396	343.07807	0.6	7	7.86	0.16	92414	4658
2511	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7	343.0796	343.07794	0.2	8.1	7.86	0.16	93535	6441
2512	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7	309.0926	343.07794	0.2	8.1	7.87	0.17	4550	234
2513	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7	308.1094	343.07794	0.2	8.1	7.87	0.17	8545	381
2514	✓	✓	✓	✓	✓	✓	Etizolam	C17H15CIN4S	342.0706	H+	343.07787	7.7	310.1005	343.07794	0.2	8.1	7.86	0.16	12757	646
2623	✓	✓	✓	✓	✓	✓	Phenazepam	C15H10BrCIN2O	347.9665	H+	348.97378	7.86		348.97459	2.3	7.1	8.03	0.17	22805	1008
2624	✓	✓	✓	✓	✓	✓	Phenazepam	C15H10BrCIN2O	347.9665	H+	348.97378	7.86	348.9733	348.97362	-0.5	2.6	8.03	0.17	47093	2269
2625	✓	✓	✓	✓	✓	✓	Phenazepam	C15H10BrCIN2O	347.9665	H+	348.97378	7.86	183.9757	348.97362	-0.5	2.6	8.01	0.15	25283	1224
2627	✓	✓	✓	✓	✓	✓	Phenazepam	C15H10BrCIN2O	347.9665	H+	348.97378	7.86	242.0609	348.97362	-0.5	2.6	8.03	0.17	4924	219
2628	✓	✓	✓	✓	✓	✓	Phenazepam	C15H10BrCIN2O	347.9665	H+	348.97378	7.86	320.9792	348.97362	-0.5	2.6	8.03	0.17	838	40
2851	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35		355.21806	0.2	12.5	6.49	0.14	151229	6069
2852	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	355.2168	355.21798	0	12.4	6.49	0.14	58779	3136
2853	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	188.1432	355.21798	0	12.4	6.49	0.14	61694	2833
2854	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	105.0701	355.21798	0	12.4	6.49	0.14	18964	926
2855	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	234.128	355.21798	0	12.4	6.49	0.14	3913	207
2856	✓	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	3632	158

Positive result: equal or better ▲▲▲▲▲

Sample: 040518AK\_084 [DEB\_15] Control: 040518AK\_033 [MPB] Rows 4688 [Process] [Cancel]







MasterView New Session



Sample	Wiff file Name	Sample Name	Number of positive results
040518AK_083	DEB_14	DEB_14	68
040518AK_084	DEB_15	DEB_15	44
040518AK_085	DEB_16_0	DEB_16_0	41
040518AK_086	DEB_12_0	DEB_12_0	70
040518AK_087	DEB_13	DEB_13	59
040518AK_088	DEB_15_0	DEB_15_0	91
040518AK_089	DEB_11_0	DEB_11_0	62
040518AK_090	MPB	MPB	10
040518AK_091	SRM	SRM	77
040518AK_092	DOP_13_0	DOP_13_0	41
040518AK_093	DOP_14	DOP_14	25
040518AK_094	DOP_15	DOP_15	81
040518AK_095	DOP_16	DOP_16	65
040518AK_096	DOP_17	DOP_17	40
040518AK_097	DOP_18	DOP_18	65
040518AK_098	DOP_19	DOP_19	53

#	Mass	RT	Isotope	Library	Formula	Name	Formula	Mass (Da)	Adduct	Extraction Mass (Da)	Expected RT (min)	Fragment Mass (Da)	Found At Mass (Da)	Error (ppm)	Isotope Ratio Difference (%)	Found At RT (min)	RT Delta (min)	Intensity	Area
2382	✓	✓	✓	✓	✓	Fentanyl	C22H28N2O	336.22016	H+	337.22744	6.2	216.1384	337.22772	0.8	6.2	6.35	0.15	2366	108
2509	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	343.07787	343.07794	0.2	8.1	7.86	0.16	135492	8755
2510	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	314.0396	343.07807	0.6	7	7.86	0.16	92414	4658
2511	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	343.0796	343.07794	0.2	8.1	7.86	0.16	93535	6441
2512	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	309.0926	343.07794	0.2	8.1	7.87	0.17	4550	234
2513	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	309.0926	343.07794	0.2	8.1	7.87	0.17	2545	381
2514	✓	✓	✓	✓	✓	Etizolam	C17H15ClN4S	342.0706	H+	343.07787	7.7	309.0926	343.07794	0.2	8.1	7.87	0.17	2757	646
2623	✓	✓	✓	✓	✓	Phenazepam	C15H10BrClN2O	347.9665	H+	348.97378	7.7	209.0926	348.97378	0.2	8.1	7.87	0.17	2805	1008
2624	✓	✓	✓	✓	✓	Phenazepam	C15H10BrClN2O	347.9665	H+	348.97378	7.7	209.0926	348.97378	0.2	8.1	7.87	0.17	7093	2269
2625	✓	✓	✓	✓	✓	Phenazepam	C15H10BrClN2O	347.9665	H+	348.97378	7.7	209.0926	348.97378	0.2	8.1	7.87	0.17	5283	1224
2627	✓	✓	✓	✓	✓	Phenazepam	C15H10BrClN2O	347.9665	H+	348.97378	7.7	209.0926	348.97378	0.2	8.1	7.87	0.17	924	219
2628	✓	✓	✓	✓	✓	Phenazepam	C15H10BrClN2O	347.9665	H+	348.97378	7.7	209.0926	348.97378	0.2	8.1	7.87	0.17	338	40
2851	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	234.126	355.21798	0	12.4	6.43	0.14	1229	6069
2852	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	3779	3136
2853	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	1694	2833
2854	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	3964	926
2855	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	3913	207
2856	✓	✓	✓	✓	✓	para-Fluorofentanyl	C22H27FN2O	354.2107	H+	355.21798	6.35	150.0706	355.21798	0	12.4	6.48	0.13	3632	158

Sample: 040518AK\_084 [DEB\_15] Control: 040518AK\_033 [MPB] Rows 4688

Unknown sample: 6069 area  
 Standard (10 ng/mL): 1054 area  
 Approx. concentration: 5 ng/mL



Sample #	Notes	Sample ID and Comments
1	Calibration Model	Reagent blank (DI water)
2		Standard 1: 100 ng/mL
3		Blank Blood -- No ISTD added
4		Standard 2: 50 ng/mL
5		Standard 3: 20 ng/mL
6		Standard 4: 10 ng/mL
7		Standard 5: 5 ng/mL
8		Standard 6: 1 ng/mL
9		Standard 7: 0.5 ng/mL
10		Standard 8: 0.25 ng/mL
11		Standard 9: 0.1 ng/mL
12		Blank Blood – with ISTD added
13	Standard Addition Assessment (5 ng/mL)	Std Add-1 (No up-spike)
14		Std Add-2 (0.2 ng/mL up-spike)
15		Std Add-3 (2 ng/mL up-spike)
16		Std Add-4 (20 ng/mL up-spike)
17	Standard Addition Assessment (10 ng/mL)	Std Add-1 (No up-spike)
18		Std Add-2 (0.2 ng/mL up-spike)
19		Std Add-3 (2 ng/mL up-spike)
20		Std Add-4 (20 ng/mL up-spike)

21	Recovery (20 ng/mL)	Pre-spike-1
22		Pre-spike-2
23		Pre-spike-3
24		Post-spike-1
25		Post-spike-2
26		Post-spike-3
27	Matrix Interferences (10 different sources)	Matrix Blood 1
28		Matrix Blood 2
29		Matrix Blood 3
30		Matrix Blood 4
31		Matrix Blood 5
32		Matrix Blood 6
33		Matrix Blood 7
34		Matrix Blood 8
35		Matrix Blood 9
36		Matrix Blood 10
37	Analyte/Internal Standard Interferences (Highest Calibrator and Normal ISTD Conc.)	Highest Cal. 1 – 100 ng/mL
38		Highest Cal. 2 – 100 ng/mL
39		Highest Cal. 3 – 100 ng/mL
40		Highest Cal. 4 – 100 ng/mL
41		Highest Cal. 5 – 100 ng/mL
42		Internal Standard 1 – 20 ng/mL
43		Internal Standard 2 – 20 ng/mL
44		Internal Standard 3 – 20 ng/mL
45		Internal Standard 4 – 20 ng/mL
46		Internal Standard 5 – 20 ng/mL





cfsre




NPS DISCOVERY







asterView

C	T	R	L	Vial file Name	Sample Name	Number of positive results	#	W	L	U	S	U	U	Name	Formula	Mass (Da)	Adduc
				010721AK_905	Matrix Blank	0	1797							Morphine-D3	C17H19D3HNO3	288.15532	H+
				010721AK_906	High QC	20	1798							Morphine-D3	C17H19D3HNO3	288.15532	H+
				010721AK_907	Mid QC	20	2281							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_908	Low QC	19	2282							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_909	Matrix Blank	20	2283							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_910	[2021-0001-1] (Blood)	27	2284							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_911	[2021-0001-1] (Blood)	20	2285							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_912	[2021-0001-1] (Blood)	6	2286							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+
				010721AK_913	[2021-0001-1] (Urine)	23	5335							Butorazepam	C24H32N4O3	424.24744	H+
				010721AK_914	[2021-0001-1] (Urine)	0	5336							Butorazepam	C24H32N4O3	424.24744	H+
				010721AK_915	[2021-0001-1] (Urine)	0	5337							Butorazepam	C24H32N4O3	424.24744	H+
				010721AK_916	[2021-0001-1] (Urine)	0	5338							Butorazepam	C24H32N4O3	424.24744	H+
				010721AK_916	[2021-0001-1] (Urine)	0	5340							Butorazepam	C24H32N4O3	424.24744	H+



asterView

C	T	R	L	Vial file Name	Sample Name	Number of positive results	#	W	L	U	S	U	U	Name	Formula	Mass (Da)	Adduc	Extraction Mass (Da)	Expected RT (min)	Fragment Mass (Da)	Found At Mass (Da)	Error (ppm)	Isotope Ratio Difference (%)	Found At RT (min)	RT Delta (min)	Intensity	Area	Lib
				010721AK_905	Matrix Blank	0	545							Methylone-D3	C11H10D3HNO3	210.10837	H+	211.11568	3.5	211.11568	2	3.9	3.57	0.07	22734	1263	Med	
				010721AK_906	High QC	20	546							Methylone-D3	C11H10D3HNO3	210.10837	H+	211.11565	3.5	117.0576	211.11608	2	3.9	3.57	0.07	16434	637	Med
				010721AK_907	Mid QC	20	2281							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	314.12121	314.12177	0.8	34	7.5	0.09	73813	4163	Alpr
				010721AK_908	Low QC	19	2282							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	286.1038	314.12177	0.8	34	7.5	0.09	114279	7574	Alpr
				010721AK_909	Matrix Blank	20	2283							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	279.1537	314.12177	0.8	34	7.5	0.09	38404	2542	Alpr
				010721AK_910	[2021-0001-1] (Blood)	27	2284							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	260.0974	314.12177	0.8	34	7.5	0.09	12657	787	Alpr
				010721AK_911	[2021-0001-1] (Blood)	20	2285							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	245.0801	314.12177	0.8	34	7.5	0.09	1728	96	Alpr
				010721AK_912	[2021-0001-1] (Blood)	6	2286							Alprazolam-O5	C17H8D2HSCIN4	313.11426	H+	314.12153	7.41	245.0801	314.12177	0.8	34	7.5	0.09	3806	222	Alpr
				010721AK_913	[2021-0001-1] (Urine)	23	5335							Butorazepam	C24H32N4O3	424.24744	H+	425.25472	7.73	425.25467	425.25466	-0.3	3	7.77	0.04	258861	12035	But
				010721AK_914	[2021-0001-1] (Urine)	0	5336							Butorazepam	C24H32N4O3	424.24744	H+	425.25472	7.73	100.1116	425.25466	-0.3	3	7.77	0.04	378926	21984	But
				010721AK_915	[2021-0001-1] (Urine)	0	5337							Butorazepam	C24H32N4O3	424.24744	H+	425.25472	7.73	72.0802	425.25466	-0.3	3	7.77	0.04	65075	3999	But
				010721AK_916	[2021-0001-1] (Urine)	0	5338							Butorazepam	C24H32N4O3	424.24744	H+	425.25472	7.73	107.0475	425.25466	-0.3	3	7.77	0.04	6119	262	But
				010721AK_916	[2021-0001-1] (Urine)	0	5340							Butorazepam	C24H32N4O3	424.24744	H+	425.25472	7.73	44.0492	425.25466	-0.3	3	7.76	0.03	2772	142	But



	A	B	C	D	E	F	G	H	I	J	K	L	M	N	
1	Concentration: 10 ng/mL				Concentration: 20 ng/mL				Recovery			Matrix	No issues		
2	Sample Name	Conc. (ng/mL)	PAR		Sample Name	Conc. (ng/mL)	PAR		Pre-1	0.157		Standard	No issues		
3	Target Sample	0	0.083		Target Sample	0	0.159		Pre-2	0.158		ISTD	No issues		
4	Up-spike #1	0.2	0.092		Up-spike #1	0.2	0.166		Pre-3	0.169		Carryover	Mininal (<1000 area)		
5	Up-spike #2	2	0.105		Up-spike #2	2	0.183		Pre-Avg	0.161					
6	Up-spike #3	20	0.252		Up-spike #3	20	0.316		Post-1	0.175					
7	Y-Intercept	-	0.0872		Y-Intercept	-	0.1636		Post-2	0.149					
8	X-Intercept	10.6	-		X-Intercept	21.4	-		Post-3	0.176					
9										Post-Avg	0.167				
10														Recovery	96.8

	A	B	C
1	WO# XXXXXXXXX		
2	CFSRE# XXXX-XXXX-X		
3	Sample Name	Conc. (ng/mL)	PAR
4	Target Sample	0	0.103
5	Up-spike #1	0.2	0.1
6	Up-spike #2	2	0.112
7	Up-spike #3	20	0.285
8	Y-Intercept	-	0.0983
9	R2 Correl	-	0.998
10	X-Intercept	10.6	-
11	Cal. Curve	11.5	-9%

Verification Data ↑

“Authentic” Sample →

# Butonitazene Quantitation

Sample ID	Concentration (ng/mL)	Peak Area Ratio (Response)	[Butonitazene] (ng/mL)
Standard Addition 1.1 (Blood)	0	0.197	
Standard Addition 1.2	0.5	0.228	
Standard Addition 1.3	5	0.554	<b>Blood</b>
Standard Addition 1.4	50	3.402	3.3
Standard Addition 2.1 (Serum)	0	0.196	
Standard Addition 2.2	0.5	0.234	
Standard Addition 2.3	5	0.687	<b>Serum</b>
Standard Addition 2.4	50	4.58	2.4
Standard Addition 3.1 (Urine)	0	1.134	
Standard Addition 3.2	0.5	1.186	
Standard Addition 3.3	5	1.713	<b>Urine</b>
Standard Addition 3.4	50	6.641	10

# Conclusions / Take Aways

- Standard addition is a scientifically valid approach for quantitation in forensic toxicology
  - Toxicologists should consider its utility in their labs
- Sample volume consumed may be an issue
- Method assessment is still **required**
- Allows for quantitation when other methods or approaches are not available
  - Particularly useful for new and emerging NPS
- *There are other ways to perform standard addition*





# Acknowledgements

- **Center for Forensic Science Research & Education (CFSRE)**

- Dr. Barry Logan
- Melissa Fogarty
- Sara Walton

- **NMS Labs**

- Dr. Sherri Kacinko
- Joseph Homan
- Donna Papsun

- **Forensic partners**



- **Provide Feedback or Insights**

- We would love to hear from you
- Fellow colleagues are looking for different perspectives and innovative approaches
- Email: [alex.krotulski@cfsre.org](mailto:alex.krotulski@cfsre.org)
- *Does your lab use standard addition?*
- *Do you have an assessment process?*
- *Do you use standard addition in a high-volume, high-throughput environment?*
- *Do you have other ideas about implementation?*





# Thank You!

## Contact Information

Alex J Krotulski, PhD

[alex.krotulski@cfsre.org](mailto:alex.krotulski@cfsre.org)

## Website/Social Media

[www.cfsre.org](http://www.cfsre.org)

[www.npsdiscovery.org](http://www.npsdiscovery.org)

*Twitter: @NPSDiscovery*

# Quantitative forensic toxicology

Consideration, experimentation  
and implementation



Discover the latest science  
with product experts  
and industry insiders

